Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Next Previous
Trial Profile

Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palifermin (Primary) ; Antithymocyte globulin; Cyclophosphamide; Degarelix; Leuprorelin; Thiotepa
  • Indications Immunosuppression
  • Focus Therapeutic Use

Most Recent Events

  • 07 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
  • 07 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
  • 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top